COMP <GO>
WVE vs AVBP // EV/EBITDA & P/E VALUATION
Wave Life Sciences Inc. (NASDAQ) VS. ArriVent BioPharma Inc. (NASDAQ) • 15-METRIC TALLY: WVE 1
— AVBP 1
■ METRIC PARITY
LAST: $3.59 (-1.10%) • MKT CAP: $708.1M
valuation
—
LAST: $14.87 (-6.77%) • MKT CAP: $733.2M
valuation
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (WVE VS. AVBP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | WVE | AVBP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -35.00% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -20.42% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | -60.50% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.85 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 2/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.0 | 34.3 | +14.70 | WVE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $708.1M | $733.2M | -$25.2M | AVBP | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | WVE REV | AVBP REV | WVE GROSS % | AVBP GROSS % | WVE FCF | AVBP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $42.7M | $497.1M | — | — | -$188.2M | -$160.6M |
| FY 2024 | $108.3M | $264.1M | — | — | -$152.0M | -$70.2M |
| FY 2023 | $113.3M | $208.9M | — | — | -$19.4M | -$55.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
WVE // BETA —
AVBP // BETA —